Hostname: page-component-76d6cb85b7-lrvh5 Total loading time: 0 Render date: 2026-07-09T21:07:08.923Z Has data issue: false hasContentIssue false
  • English
  • Français

Testing Multiple Novel Mechanisms for Treating Schizophrenia in a Single Trial

Published online by Cambridge University Press:  02 March 2006

Herbert Y. Meltzer
Herbert Y. Meltzer
Affiliation:
Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA; Email: herbert.meltzer@vanderbilt.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Schizophreniaclinical trialosanetrantNK3 antagonist5-HT2A/C antagonistcentral cannabinoid antagonistneurotensin antagonist

Information

Type
Review Article
Information
Progress in Neurotherapeutics and Neuropsychopharmacology , Volume 1 , Issue 1 , January 2006 , pp. 115 - 120
Copyright
© 2006 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Bonaccorso, S., Meltzer, H.Y., Li, Z., Dai, J., Alboszta, A.R., & Ichikawa, J. (2002). SR46349-B, a 5HT2 receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex via 5HT1A receptor activation. Neuropsychopharmacology, 27, 430–441.Google Scholar
Boules, M., Fredrickson, P., & Richelson, E. (2005). Neurotensin agonists as an alternative to antipsychotics. Expert Opinion Investigational Drugs, 4, 359–369.Google Scholar
Kane, J., Honigfeld, G., Singer, J., & Meltzer, H.Y. (1988). The Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.Google Scholar
Kay, S.R., Fiszbein, A., & Opler, L.A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bull, 13, 261–276.Google Scholar
Meltzer, H.Y. (1997). Treatment-resistant schizophrenia – the role of clozapine. Current Medical Research and Opinion, 14 (1), 1–20.Google Scholar
Meltzer, H.Y. (2001). Serotonin as a target for antipsychotic drug action. In: Breier, A., Tran, P., Herrea, J.M., Tollefson, G.D., & Bymaster, F.P. (eds.), Current Issues in the Psychopharmacology of Schizophrenia, Chapter 17. Philadelphia: Lippincott Williams & Wilkins Healthcare, pp. 289–303.
Meltzer, H.Y. (2005). The metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences? International Journal of Neuropsychopharmacology, 8, 153–156.Google Scholar
Meltzer, H.Y., Arvanitis, L., Bauer, D., & Rein, W. (2004). A placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. American Journal of Psychiatry, 161, 975–984.Google Scholar
Poncelet, M., Barnouin, M.C., Breliere, J.C., Le Fur, G., & Soubrie, P. (1999). Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology (Berl), 144 (2), 144–150.Google Scholar
Roth, B.L., & Xia, Z. (2004). Molecular and cellular mechanisms for the polarized sorting of serotonin receptors: relevance for genesis and treatment of psychosis. Critical Reviews in Neurobiology, 16, 229–236.Google Scholar
Spooren, W., Riemer, C., & Meltzer, H.Y. (in press). NK3 receptor antagonists: the next generation of anti-psychotics? Nature Reviews Drug Discovery, 2005; 4: 967–975Google Scholar
Woodward, N.D., Purdon, S.E., Meltzer, H.Y., & Zald, D.H. (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacolgy, 8, 1–16.Google Scholar